A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Multi- Site Phase 2b Clinical Study to Assess the Efficacy, Safety and Tolerability Patients With Mild to Moderate Onychomycosis
Latest Information Update: 24 Dec 2018
At a glance
- Drugs NP 213 (Primary)
- Indications Onychomycosis
- Focus Therapeutic Use
- Sponsors Taro Pharmaceuticals USA
- 21 Aug 2018 Status changed from recruiting to completed.
- 17 May 2018 Planned End Date changed from 1 May 2018 to 1 Jun 2018.
- 17 May 2018 Planned primary completion date changed from 1 Apr 2018 to 1 May 2018.